Literature DB >> 20185966

Real-time RT-PCR analysis for evaluating the Her2/neu status in breast cancer.

M Cuadros1, P Talavera, F J López, I García-Peréz, A Blanco, A Concha.   

Abstract

OBJECTIVE: The Her2/neu status is of great clinical value in breast tumor patients. Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) techniques are the test of choice for many practicing pathologies. The main objective of this retrospective study was to investigate the relationship between Her2/neu breast cancer amplification and overexpression (DNA, mRNA and protein).
METHODS: To accomplish this goal, we evaluated Her2/neu mRNA expression by real-time quantitative RT-PCR, gene amplification by FISH and protein expression by IHC.
RESULTS: An excellent correlation between FISH and IHC Her2/neu results was observed, confirming that protein levels were directly related to DNA amplification. Polysomy 17 was frequently found in tumors showing Her2/neu overexpression. However, we did not find any statistically significant correlation among DNA, mRNA and protein levels, suggesting that Her2/neu could be post-transcriptionally regulated.
CONCLUSIONS: There was a highagreement between Her2/neu gene amplification and protein overexpression but not mRNA expression levels. Nevertheless, IHC3+ and FISH-positive tumors indicated higher expression levels of Her2/neu mRNA by RT-PCR than those observed in IHC and FISH-negative tumors. These findings question the relevance of quantitative RT-PCR in routine assessment of Her2/neu overexpression in human breast cancer in the clinical laboratory setting. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20185966     DOI: 10.1159/000272953

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  7 in total

1.  HER2 status in breast cancer: experience of a Spanish National Reference Centre.

Authors:  Marta Cuadros; Carlos Cano; Francisco Javier López; Paloma Talavera; Inmaculada García-Peréz; Armando Blanco; Ángel Concha
Journal:  Clin Transl Oncol       Date:  2011-05       Impact factor: 3.405

2.  Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches.

Authors:  J Lehmann-Che; F Amira-Bouhidel; E Turpin; M Antoine; H Soliman; L Legres; C Bocquet; R Bernoud; E Flandre; M Varna; A de Roquancourt; L-F Plassa; S Giacchetti; M Espié; C de Bazelaire; L Cahen-Doidy; E Bourstyn; A Janin; H de Thé; P Bertheau
Journal:  Br J Cancer       Date:  2011-05-03       Impact factor: 7.640

3.  Defining the sister rat mammary tumor cell lines HH-16 cl.2/1 and HH-16.cl.4 as an in vitro cell model for Erbb2.

Authors:  Sandra Louzada; Filomena Adega; Raquel Chaves
Journal:  PLoS One       Date:  2012-01-10       Impact factor: 3.240

4.  ERBB2 in cat mammary neoplasias disclosed a positive correlation between RNA and protein low expression levels: a model for erbB-2 negative human breast cancer.

Authors:  Sara Santos; Cláudia S Baptista; Rui M V Abreu; Estela Bastos; Irina Amorim; Ivo G Gut; Fátima Gärtner; Raquel Chaves
Journal:  PLoS One       Date:  2013-12-26       Impact factor: 3.240

5.  The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer.

Authors:  Elisabeth Hofmann; Rita Seeboeck; Nico Jacobi; Peter Obrist; Samuel Huter; Christian Klein; Kamil Oender; Christoph Wiesner; Harald Hundsberger; Andreas Eger
Journal:  Biomark Res       Date:  2016-04-07

6.  Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases.

Authors:  Gabriele Zoppoli; Anna Garuti; Gabriella Cirmena; Ludovica Verdun di Cantogno; Cristina Botta; Maurizio Gallo; Domenico Ferraioli; Enrico Carminati; Paola Baccini; Monica Curto; Piero Fregatti; Edoardo Isnaldi; Michela Lia; Roberto Murialdo; Daniele Friedman; Anna Sapino; Alberto Ballestrero
Journal:  J Transl Med       Date:  2017-05-01       Impact factor: 5.531

7.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes
Journal:  Arch Pathol Lab Med       Date:  2013-10-07       Impact factor: 5.534

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.